What happened
A new Nature Biotechnology paper on DNA-guided CRISPR-Cas12 for cellular RNA targeting is interesting because RNA is where biology becomes dynamic. DNA edits can be permanent. RNA targeting can be more adjustable, more temporal, and potentially better suited to diseases where controlling expression matters more than rewriting the genome.
That distinction matters for biotech strategy. The most valuable platforms may not be the ones that make the biggest edit. They may be the ones that offer the right amount of control, in the right cell, for the right duration.
This is the kind of platform shift that can quietly change therapeutic design.
Source
Reported by DNA-guided CRISPR-Cas12 for cellular RNA targeting via nature.com, published May 15, 2026.